A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

Suppiah, Ravi, Judge, Andrew, Batra, Rajbir, Flossmann, Oliver, Harper, Lorraine, Höglund, Peter, Javaid, M Kassim, Jayne, David, Mukhtyar, Chetan ORCID: https://orcid.org/0000-0002-9771-6667, Westman, Kerstin, Davis, John C, Hoffman, Gary S, McCune, W Joseph, Merkel, Peter A, St Clair, E William, Seo, Philip, Spiera, Robert, Stone, John H and Luqmani, Raashid (2011) A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care & Research, 63 (4). pp. 588-596. ISSN 2151-464X

Full text not available from this repository. (Request a copy)

Abstract

OBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. RESULTS: Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11-1.90), diastolic hypertension (OR 1.97, 95% CI 0.98-3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20-0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). CONCLUSION: Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status.

Item Type:	Article
Additional Information:	Copyright © 2011 by the American College of Rheumatology.
Uncontrolled Keywords:	adult,aged,complications,cohort studies,female,follow-up studies,complications,humans,logistic models,male,complications,middle aged,predictive value of tests,regression analysis,risk factors,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	LivePure Connector
Date Deposited:	27 Nov 2019 02:00
Last Modified:	22 Oct 2022 05:29
URI:	https://ueaeprints.uea.ac.uk/id/eprint/73097
DOI:	10.1002/acr.20433

Actions (login required)

View Item